Biogen Inc. BIIB
Biogen's Q2 2026 earnings beat ($3.60 vs $2.96 consensus) and raised full-year guidance mark an inflection point where the growth portfolio — Leqembi and rare-disease drugs — is finally offsetting legacy MS erosion, supporting a shift from hold to buy. The stock's technical structure is constructive at $209.83, trading above both the 50-day ($203.34) and 200-day ($186.38) moving averages with positive MACD momentum, while FY2025 free cash flow of $2.05B provides a solid floor.
Valuation is the main tension: at 36.9x trailing earnings versus a peer median of 26.7x, the market is pricing in a recovery that Q2 2026 results begin to validate, but the premium leaves limited room for disappointment.
What could go wrong
- Valuation premium. PE of 36.9x is 38% above peer median of 26.7x; EV/EBITDA of 22.8x is 45% above peer median of 15.8x, leaving little margin for error if growth disappoints.
- Margin compression trend. FY2025 gross margin fell to 70.5% from 76.1% in FY2024, with operating income declining 24.5% to $1.88B — if this trend persists despite revenue growth, earnings quality is questionable.
- Smart-money outflows. Smart-money score turned slightly negative at -0.0083 as of Q1 2026, down from 0.1262 in mid-2024, suggesting institutional conviction is waning even as the stock rallies.
- Insider selling. Net insider value sold over 24 months is -$8.5M across 143 transactions, with recent sales by director Minor Lloyd at ~$200-203 per share.
What would change my mind
Where this comes from: Benzinga news, 2026-07-29 · Zacks Investment Research, 2026-07-29 · FMP fundamentals FY2025 · FMP fundamentals FY2025. Orin's read on BIIB; not advice.
Twelve months actual closes to 2026-09-23 · actual filings
50-day average 200-day average · volume below
On file
All BIIB filingsLargest holders · 13F Q2 2026
Money flow| Filer | Position | Of fund |
|---|---|---|
| Fmr | $3.9B | 0.2% of fund |
| Vanguard Capital Management | $2.1B | 0.0% of fund |
| State Street | $1.6B | 0.0% of fund |
| Vanguard Portfolio Management | $1.4B | 0.1% of fund |
| Geode Capital Management | $957.9M | 0.1% of fund |
| Wellington Management Group Llp | $673.6M | 0.1% of fund |
89 filers · quarter ended Q2 2026 · positions, not flows
Insiders, last 24 months: 144 Form 4 filings, net −$8.5M. Of the 50 on hand, 1 was an open-market purchase and 3 sales— the rest are grants, option exercises and tax withholding.
Ask Orin about BIIB
Orin answers questions about BIIB from its filings, transcripts and numbers — with the source behind every claim. Your own desk starts with 3 free days, card required.
Start 3 free days →Where it trades
| Metric | Now | Own median | Sector |
|---|---|---|---|
| P/E | 40.1× | 20.0× | 26.4× |
| EV/EBITDA | 24.4× | 10.5× | — |
| P/S | 3.38× | 3.26× | — |
| P/B | 1.8× | 2.5× | — |
Its P/E sits above all 5 of the last 5 years (+2.81σ from its own mean).
5.0%
free-cash-flow growth every year for 10 years, discounted at 10%, is what today’s price implies — starting from $2.1B of trailing free cash flow. It is an assumption the market is making, not a forecast Orin is making.
What Wall Street published
$246
$175 – $300 · +8% against today's price
- 31 buy or overweight
- 17 hold
- 1 underweight or sell
The analysts’ consensus and their own ratings, not Orin’s. A target is a twelve-month opinion published by the firm that wrote it.
Against the companies it is compared to
| Company | Market cap | P/E | EV/EBITDA | Gross | Net | ROE |
|---|---|---|---|---|---|---|
| BIIBBiogen Inc. | $34B | 40.1× | 24.4× | 67.7% | 8.4% | 5% |
| DGXQuest Diagnostics Incorporated | $26B | 24.4× | 15.7× | 33.1% | 9.2% | 14% |
| DXCMDexCom, Inc. | $33B | 33.9× | 21.4× | 62.5% | 20.1% | 36% |
| INCYIncyte Corporation | $25B | 15.3× | 10.4× | 92.6% | 27.7% | 30% |
| LHLabcorp Holdings Inc. | $25B | 25.0× | 14.7× | 27.8% | 7.0% | 12% |
| PODDInsulet Corporation | $9B | 25.5× | 15.5× | 71.1% | 12.3% | 27% |
| STESTERIS plc | $20B | 25.6× | 12.2× | 44.4% | 13.3% | 11% |
| WATWaters Corporation | $41B | 104.6× | 51.4× | 50.8% | 3.6% | 2% |
The median is of the 7 peers listed above and nothing else — check it against the column. This company trades 57.3% above it. The peer set is the vendor’s, so a company can appear here that a person would not have chosen.
What it has traded at
What its sector has traded at
Two scales, drawn separately on purpose: a sector median and one company’s multiple are not the same number and putting them on one axis invites a comparison neither series supports.
Discounted cash flow
| Model | Fair value | Against | Computed |
|---|---|---|---|
| Standard DCF | $660 | $196.72 · +235% | 2026-06-10 |
| Levered DCF | $412 | $196.72 · +109% | 2026-06-10 |
The vendor’s intrinsic-value models. Treat them as a low-growth anchor — for a fast grower the market routinely pays well above a DCF. These were computed against the price in the “against” column, not today’s.
Every estimate on one scale
The vertical rule is the current price. Ranges and point estimates are the backend’s, published as they were calculated; an arrow means the estimate sits beyond this scale, and its number is on the right.